Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction

Advanced Accelerator Applications SA

Division of Novartis AG
www.adacap.com

Latest From Advanced Accelerator Applications SA

Bookmark
  • Analysis

CDER's Novel Approvals In 2018 Show Remarkable Review Consistency

By Bridget Silverman
Years of regulatory fine-tuning culminated in record low average time to approval of 9.9 months for novel agents at US FDA’s drug center.
Drug Review Drug Approval Standards
Bookmark
  • Analysis

Novartis R&D Chief Tsai On 2019 Goals, Priorities, BD And Digital Advances

By Jessica Merrill

R&D head John Tsai spoke with Scrip about culture change at Novartis as it moves toward advanced therapy platforms and embraces digital technologies, and offered a peek into what’s in store for R&D in 2019 and beyond.

Leadership Companies
Bookmark
  • Analysis

In A Record Year For US FDA Approvals, Pfizer Came Out On Top

By Mary Jo Laffler and Bridget Silverman
FDA’s approval teams cleared a total of 65 new molecular entities and novel biologics in 2018, blowing past previous records. Scrip looks at how that breaks down for industry leaders. 
Approvals Drug Review
Bookmark
  • Analysis

Scrip’s Top Five Stories Of 2018

By Alex Shimmings

A look back at the Scrip stories that piqued the most interest for our readers in 2018. 

Companies Commercial
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Stefano Buono, CEO
    Heinz Mausli, CFO
    Claude Hariton, Head, R&D
    Gerard Ber, COO
  • Contact Info
  • Advanced Accelerator Applications SA
    Phone: 4 50 99 30 70
    20 Rue Diesel
    Saint Genis Pouilly, 01630
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By